Foghorn Therapeutics (FHTX) Current Assets (2019 - 2026)

Foghorn Therapeutics' Current Assets history runs 8 years deep, the most recent figure standing at $188.1 million for Q1 2026.

• In Q1 2026, Current Assets fell 16.57% year-over-year to $188.1 million; the TTM figure through Mar 2026 stood at $188.1 million (down 16.57% YoY), while the FY2025 annual figure was $163.2 million, down 34.6% from the prior year.
• Current Assets for Q1 2026 stood at $188.1 million, up from $163.2 million in the prior quarter.
• The five-year high for Current Assets was $429.8 million in Q1 2022, with the low at $163.2 million in Q4 2025.
• The 5-year median for Current Assets is $265.4 million (2023), against an average of $274.3 million.
• The sharpest annual moves came in 2022 and 2025: Current Assets surged 204.76% in 2022, then sank 34.6% in 2025.
• Foghorn Therapeutics' Current Assets stood at $351.4 million in 2022, then plunged by 31.65% to $240.2 million in 2023, then gained by 3.92% to $249.6 million in 2024, then tumbled by 34.6% to $163.2 million in 2025, then grew by 15.21% to $188.1 million in 2026.
• Business Quant data shows FHTX's Current Assets at $188.1 million in Q1 2026, $163.2 million in Q4 2025, and $184.1 million in Q3 2025.